Dr. Novobrantseva brings deep knowledge and broad experience in immunology/inflammation, cancer, immuno-oncology, autoimmunity and fibrosis to NextPoint, along with an outstanding record of accomplishment in drug development across immuno-oncology discovery and antibody development.

“Tatiana is a star in the immuno-oncology world, and we are thrilled to welcome her to the NextPoint team,” said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. “Her strategic leadership and entrepreneurial spirit will be instrumental during this pivotal time for NextPoint’s growth as we advance our precision immuno-oncology programs targeting the HHLA2 pathway.”

Dr. Novobrantseva co-founded Verseau Therapeutics in 2017 and served as Chief Scientific Officer for over 5 years, advancing immunotherapies stimulating macrophage repolarization to initiate anti-cancer immune responses, and is currently an Advisor to Verseau. Additionally, Dr. Novobrantseva previously led oncology discovery and development projects at Moderna as Chief Scientific Officer, Immuno-Oncology Research. She serves on the Scientific Advisory Boards of Voro Therapeutics and FairJourney Biologics, as well as on the Advisory Board for the mentorship organization Women in the Enterprise of Science and Technology.

After earning a PhD from the University of Cologne in Germany, Dr. Novobrantseva completed postdoctoral research at Harvard Medical School in the laboratory of Dr. Klaus Rajewsky on B cell immunology and autoimmunity. She advanced in industry as a scientist at Biogen and Alnylam Pharmaceuticals. Dr. Novobrantseva then participated in building Jounce Therapeutics as Director of Research, leading programs to reactivate the immune system against cancer, before consulting on a freelance basis on immunological aspects of drug development for various biopharma companies, developing scientific strategies across therapeutic areas for discovery and preclinical development.

“NextPoint takes a highly innovative approach to harnessing the immune system to fight cancer, which has been a personal mission of mine for more than a decade,” commented Dr. Novobrantseva. “I am thrilled to build on this exciting approach to deliver novel, precision immuno-oncology therapeutics to patients with currently intractable cancers.”

About NextPoint Therapeutics

NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our innovative approach integrates foundational science with a defined clinical biomarker strategy to deliver a new class of monotherapies for patients who do not benefit from PD-1/L1 inhibitors. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. To learn more, visit nextpointtx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240116614410/en/